Oncolix Overview
- Year Founded
-
2007
- Status
-
Out of Business
- Employees
-
2
- Latest Deal Type
-
Out of Business
Oncolix General Information
Description
Developer of therapeutic drugs for cancer treatment designed to bind to the prolactin receptor. The company engages in the development of medical therapies for the treatment of various cancers including ovarian, breast, uterine, and prostate, enabling healthcare operators to get cancer treatment disease drugs.
Contact Information
Website
www.oncolixbio.comCorporate Office
- 14405 Walters Road
- Suite 780
- Houston, TX 77014-1355
- United States
Corporate Office
- 14405 Walters Road
- Suite 780
- Houston, TX 77014-1355
- United States
Oncolix Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Out of Business | 03-Apr-2024 | Completed | Out of Business | |||
| 5. Reverse Merger | 03-Aug-2017 | Completed | Clinical Trials - Phase 1 | |||
| 4. Later Stage VC | Completed | Clinical Trials - Phase 1 | ||||
| 3. Later Stage VC | 06-Feb-2017 | Completed | Clinical Trials - Phase 1 | |||
| 2. Later Stage VC (Series A) | 22-Jan-2015 | $4.2M | $8.15M | Completed | Clinical Trials - Phase 1 | |
| 1. Seed Round | 14-May-2013 | $3.95M | $3.95M | Completed | Clinical Trials - Phase 1 |
Oncolix Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
Oncolix Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Oncolix Patents
Oncolix Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2019169330-A1 | Method for treating cancers expressing prolactin receptor | Inactive | 02-Mar-2018 | ||
| JP-2016029110-A | Prolactin receptor antagonist and use of chemotherapeutic agent for treating ovarian cancer | Pending | 17-Nov-2010 | ||
| JP-2018062527-A | Prolactin receptor antagonist and use of chemotherapeutic agent for treating ovarian cancer | Inactive | 17-Nov-2010 | ||
| AU-2011328935-A1 | Use of prolactin receptor antagonist and chemotherapeutic drug for treating ovarian cancer | Active | 17-Nov-2010 | ||
| AU-2011328935-B2 | Use of prolactin receptor antagonist and chemotherapeutic drug for treating ovarian cancer | Inactive | 17-Nov-2010 | A61K38/2257 |
Oncolix Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Oncolix Acquisitions (1)
Oncolix’s most recent deal was a Merger/Acquisition with Advanced Environmental Petroleum Producers. The deal was made on 07-Aug-2017.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Advanced Environmental Petroleum Producers | 07-Aug-2017 | Merger/Acquisition | Energy Production |
Oncolix Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Advanced Environmental Petroleum Producers | Houston, TX | 2013 |
Oncolix FAQs
-
When was Oncolix founded?
Oncolix was founded in 2007.
-
Where is Oncolix headquartered?
Oncolix is headquartered in Houston, TX.
-
What is the size of Oncolix?
Oncolix has 2 total employees.
-
What industry is Oncolix in?
Oncolix’s primary industry is Drug Discovery.
-
Is Oncolix a private or public company?
Oncolix is a Private company.
-
What is Oncolix’s current revenue?
The current revenue for Oncolix is .
-
How much funding has Oncolix raised over time?
Oncolix has raised $15M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
